![aion database composite aion database composite](https://cloudfront-us-east-1.images.arcpublishing.com/coindesk/GTKX3V3AMJFW3DM2JDIBAQBGW4.jpg)
De La Haye continued, "As a Johns Hopkins Alumnus, it is our intention to follow the best treatment protocols like those being established at Johns Hopkins Center for Psychedelic and Consciousness Research."Īion International Center for Psychedelic Psychiatry, in addition to treating patients, looks forward to collaborating with The UWI and other Tertiary Institutions in Jamaica in the research and development of cutting edge, effective and safe products for treating patients with mental illness. Psychedelic Psychiatry has the potential to change the lives of millions of patients, reducing their disability and improving their quality of life." Dr. De La Haye stated, "We need all available and effective products for the treatment of patients with mental illness. He is also a former Captain in the Jamaica Defense Force.ĭr.
AION DATABASE COMPOSITE REGISTRATION
De La Haye established the Medicinal Cannabis Unit in the Ministry of Health and Wellness (MOHW) in July 2017, supervising the registration of over 80 medicinal cannabis products in Jamaica. De La Haye is a Past Chief Medical Officer in the Ministry of Health and Wellness in Jamaica, Member of the Medical Council of Jamaica, Member of the International Society for Substance Use Professionals (ISSUP), Past President of the Medical Association of Jamaica, Past President of the Jamaica Psychiatric Association, Past President of the Jamaica Fulbright Alumni Association, Past Chairman of the Bellevue Hospital Board of Management, and Past Deputy Chairman of the National Council on Drug Abuse in Jamaica.ĭr.
![aion database composite aion database composite](https://aionfx.com/app/themes/aionfx/img/aion_logo_og.png)
AION DATABASE COMPOSITE PROFESSIONAL
He is an Internationally Certified Addiction Professional and a Global Master Trainer of Trainers in the Treatment of Substance Use Disorders.ĭr. He completed his MD (Cum Laude) at the University of Pecs in Hungary, his Postgraduate Degree in Psychiatry at the UWI, his Masters in Public Health (Cum Laude) and a Fulbright Fellowship in Substance Abuse at the Johns Hopkins University (JHU). De La Haye is Deputy Dean in the Faculty of Medical Sciences, The University of the West Indies (UWI), Mona, Jamaica and a Consultant General and Addiction Psychiatrist at the University Hospital of the West Indies (UHWI). The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, M.D., M.P.H, D.M., I.C.A.P.
![aion database composite aion database composite](https://i.ebayimg.com/images/g/YdIAAOSw-zpfNEAH/s-l300.jpg)
Assuming the same distribution of costs across lower-income and higher-income countries holds for all other countries (representing 20% of the world's population), the global cost per year is $1.15 trillion." In the United States, approximately 10% of the adult population has been diagnosed with MDD in the past 12 months, and the yearly economic burden of MDD is estimated to be $210 billion." "Across the 36 largest countries in the world, in the absence of scaled-up treatment, it is projected that more than 12 billion days of lost productivity (equivalent to more than 50 million years of work) are attributable to depression and anxiety disorders every year, at an estimated cost of US $925 billion. Depression is the number one cause of disability, and the relative risk of all-cause mortality for those with depression is 1.7 times greater than the risk for the general public. "MDD is a substantial public health concern, affecting more than 300 million individuals worldwide. Food and Drug Administration (FDA) recently designated psilocybin therapy as a "breakthrough therapy" for the treatment of MDD. In addition, the Center will be studying the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), and anorexia nervosa.
![aion database composite aion database composite](https://1.bp.blogspot.com/-o-MXqsBiUto/Vr5C-WB1Z0I/AAAAAAAAUfA/TAWXjoITU90/s1600/aion%2Bcrafting.jpg)
The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol, and other drug misuse), depression and anxiety associated with life-threatening illnesses, treatment-resistant depression, and major depressive disorder (MDD). (CSE: AION) (" Aion Therapeutic" or the " Company") announced today the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. February 23, 2021) - Aion Therapeutic Inc.